Search Results for: "Clinic Roundup"
-
Clinic Roundup
TapImmune Inc., of Seattle, said the Mayo Clinic received investigational new drug application allowance for a Phase I trial of the company's HER-2/neu vaccine in breast cancer patients who finished standard Herceptin (trastuzumab, Roche AG)-based therapy and are at high risk of disease recurrenceBioWorld Today | Monday, May 7, 2012 -
Clinic Roundup
Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., said it submitted an investigational new drug application for a Phase I trial of lead cancer drug LB-100, which demonstrated in preclinical models an ability to kill cancer cells by inhibiting cancer cell growth and to enhance the killing of cancer cells via widely used drugs such as temozolomide, doxorubicin and docetaxelBioWorld Today | Wednesday, May 2, 2012 -
Clinic Roundup
The company plans to request a pre-new drug application meeting with the FDA to discuss a U.SBioWorld Today | Thursday, April 19, 2012 -
Clinic Roundup
ImmunoGen Inc., of Waltham, Mass., said its investigational new drug application for IMGN853,which combines the company's cancer-cell-killing agent DM4 to its M9346A FOLR1-targeting antibody, is now activeBioWorld Today | Wednesday, April 18, 2012 -
Clinic Roundup
Cerecor Inc., of Baltimore, said its investigational new drug application for FP01 for the treatment of cough cleared the FDABioWorld Today | Thursday, April 12, 2012 -
Clinic Roundup
Based on the findings, the company said it will file a supplemental new drug application midyear with a request for priority reviewBioWorld Today | Friday, April 6, 2012 -
Clinic Roundup
Aradigm Corp., of Hayward, Calif., said the FDA approved its investigational new drug application for a pivotal Phase III trial of Pulmaquin (dual-release ciprofloxacin for inhalation) in noncystic fibrosis bronchiectasis...Watson expects to complete the trial by fourth-quarter 2013, followed by the submission of a new drug application to the FDABioWorld Today | Tuesday, March 13, 2012 -
Clinic Roundup
Gilead, which reported top-line data from Study 102 in August 2011, submitted a new drug application for Quad late last year. (See BioWorld Today, Aug. 16, 2011BioWorld Today | Friday, March 9, 2012 -
Pharma: Clinic Roundup
Results from an additional Phase III study are expected this spring, and the companies anticipate filing a new drug application later this yearBioWorld Today | Thursday, March 8, 2012 -
Clinic Roundup
CK Life Sciences International (Holdings) Inc., of Hong Kong, said the FDA cleared the investigational new drug application submitted by its subsidiary, Polynoma LLC, allowing it to proceed with Phase III testing of its melanoma vaccine, manufactured using a combination of antigens from three melanoma cell lines...Marshall Edwards Inc., of San Diego, submitted an investigational new drug application (IND) to the FDA for oncology drug candidate ME-344, its lead mitochondrial inhibitorBioWorld Today | Wednesday, March 7, 2012 -
Clinic Roundup
The data, which were included in the company's new drug application, showed treatment significantly reduced spleen volume and improved symptoms of myelofibrosisBioWorld Today | Friday, March 2, 2012 -
Clinic Roundup
Tau Therapeutics LLC, of Charlottesville, Va., said the FDA accepted its investigational new drug application for T-type calcium channel blocker mibefradil, and the firm anticipates launching a Phase I trial in healthy volunteers March 2BioWorld Today | Wednesday, February 29, 2012 -
Clinic Roundup
Tau Therapeutics LLC, of Charlottesville, Va., said the FDA accepted its investigational new drug application for T-type calcium channel blocker mibefradil, and the firm anticipates launching a Phase I trial in healthy volunteers March 2BioWorld Today | Wednesday, February 29, 2012 -
Clinic Roundup
In August 2011 , Gentium voluntarily withdrew its new drug application for defibrotide after receiving a letter from the FDA citing numerous refuse-to-file issuesBioWorld Today | Tuesday, February 28, 2012 -
Clinic Roundup
S1 Pharmaceuticals Inc., of Jersey City, N.J., said it submitted an investigational new drug application for Phase Ib studies of SIP-104 (Lorexys), its lead candidate for hypoactive sexual desire disorder (HSDD) and female sexual dysfunctionBioWorld Today | Wednesday, February 22, 2012 -
Clinic Roundup
Coronado Biosciences Inc., of Burlington, Mass., said it filed an investigational new drug application for CNDO-109, a biologic designed to prime natural killer cells without the need for cytokines (IL-2) for use in high-risk acute myeloid leukemia (AMLBioWorld Today | Wednesday, February 15, 2012 -
Clinic Roundup
Titan plans to submit a new drug application for Probuphine, a subcutaneous implant formulation of buprenorphine, in the third quarterBioWorld Today | Friday, February 10, 2012 -
Clinic Roundup
Neurelis Inc., of San Diego, said the FDA cleared the investigational new drug application for NRL-1, an intranasal diazepam formulation, to begin clinical trials in acute breakthrough seizures...An interim analysis and new drug application resubmission is planned once about 87 MACE events have occurred, which is anticipated to be less than two years from the start of the studyBioWorld Today | Tuesday, February 7, 2012 -
Clinic Roundup
A supplemental new drug application is expected to be submitted in the first half of this yearBioWorld Today | Friday, February 3, 2012 -
Clinic Roundup
AMAG plans to submit a supplemental new drug application for an expanded U.SBioWorld Today | Tuesday, January 31, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.